Valion Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VBIO Nasdaq 2830 valionbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Valion Bio, Inc.

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - Jun 25th, 2026 5:45 am
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures - Jun 11th, 2026 5:45 am
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME - May 19th, 2026 2:38 pm
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform - May 14th, 2026 2:30 pm
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS - May 14th, 2026 2:05 pm
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 - May 11th, 2026 6:01 am
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™ - May 6th, 2026 6:08 am
VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION - May 5th, 2026 6:00 am
Valion Bio Appoints Melinda Lackey as General Counsel - May 4th, 2026 2:05 pm
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME - Apr 28th, 2026 6:01 am